Analyses were restricted to subjects aged 18 years or older. We instructed studies not to impute the two key kidney measures, eGFR (i.e., age, gender, race, and serum creatinine) and albuminuria. Values of eGFR >200 were treated as 200. Zero values of ACR were treated as 0.1 for log transformation. For other variables in the models with missing values we imputed with the mean value of the covariate. Individuals with practically impossible values of covariates, i.e., systolic blood pressure <50 or >300 mmHg or BMI <10 or >100 kg/m 2 were excluded from the analysis (<0.01 %).
For 35 of the 46 studies analysis was done at the Data Coordination Center at Johns Hopkins University; for the remainder the standard code was run in-house at individual study centers, with the output returned to the Data Coordinating Center. The code was written in STATA by the Data Coordinating Center. The standard code was designed to automatically save all output needed for the meta-analysis. The Data Coordinating Center then pooled the estimates across studies using STATA. Studies with outcomes fewer than 10 in any strata for particular analysis were excluded.
Studies were instructed to standardize and calibrate their serum creatinine to their best ability and report the method of standardization. The reported creatinine calibration allows grouping studies into studies that reported using an IDMS traceable method or conducted some serum creatinine calibration to IDMS traceable methods (AKDN, AusDiab, Beaver Dam, Geisinger, GLOMMS-1, Gubbio, HUNT, KEEP, KPNW, MMKD, NephroTest, NHANES III, Okinawa 83 and 93, Rancho Bernardo, REGARDS) and studies where the creatinine standardization was not done (AASK, ADVANCE, Aichi, ARIC, British Columbia CKD, Beijing, CARE, CHS, CIRCS, COBRA, CRIB, ESTHER, Framingham, IPHS, KP Hawaii, MASTERPLAN, MDRD, MESA, MRC Older People, MRFIT, Ohasama, Pima, PREVEND, RENAAL, Severance, STENO, Sunnybrook, Taiwan, ULSAM, ZODIAC). Retrospective assessment of creatinine calibration without direct collection of laboratory data is limited since substantial creatinine calibration differences have been documented even within a single laboratory using the same method over time.
Reference ranges are important for anchoring the figure and conducting statistical significance tests but do not alter the shape of the spline across the full range of exposure. CKD-PC usually uses the reference range of eGFR 90-104 ml/min/1.73 m 2 (95 for continuous analysis) for general population and high-risk cohorts. However, given that few people in the oldest age category had eGFR in this range (2.3%) and thus very few events (particularly ESRD) were observed in this eGFR range, we selected a lower eGFR category of 75-89 (80 for continuous) ml/min/1.73 m 2 as the reference range for the present study. Similarly, ACR of 10 mg/g, instead of 5 mg/g, was set as the reference point for this study.
Piecewise-linear splines were used to allow for non-linear association in a manner that still allows for a simple interpretation of the association within each segment and transparently shows changes in slope at clinically interpretable points. Estimates and standard errors for each point are the combination of all terms between that point eAppendix 2. Data Analysis Overview and Analytic Notes for Some Individual Studies (continued) and the reference point with covariances used for standard error estimates. For points in the same linear segment as the reference points (eGFR 75-90 for eGFR=80 and ACR <30 for ACR=10) statistical significance compared to the reference point is only dependent on the statistical significance of the slope for that segment. If the slope is statistically significant, all points on the segment will be statistically significant since smaller effect sizes near the reference point have proportionately small standard errors and the same statistical significance test.
Adjusted average absolute risk was calculated using the weighted average incidence rates in the reference age category (55-64 years) at the reference range of eGFR (75-89 ml/min/1.73 m 2 ) or ACR (<30 mg/g) combined with the meta-analyzed adjusted HRs for each level of eGFR and ACR. The weights were from the random effects metaanalysis for HRs at adjacent points to the reference eGFR (80 ml/min/1.73m 2 ) and ACR (10 mg/g) point in the spline models. For example, the weighted average total mortality rate was 10.1 deaths/1000 person years at eGFR=80 for age 55-64. The adjusted hazard ratios then allowed for calculation of adjusted average mortality rates for all eGFR and age groups assuming this reference value. The main effect of the age categories resulted in average mortality rates of 4.0, 23.3 and 57.8 (per 1000 person-years) for age groups 18-54, 65-74 and 75+ years. The full spline model including interactions then allowed for calculation of all other values. For example, the mortality rate at age 75+ and eGFR=45 years is calculated as the product of the reference mortality rate times the adjusted hazard ratio for this point as 10.09*8.427=85.0. Standard errors for the comparison to the reference value (eGFR=80 at age 55-64 years) were calculated using the delta method 49 and used for significance testing. This statistical test (shown in panels C and D) should be interpreted as the combined association of both age category and eGFR (for example eGFR=45 at age 75+ years vs. eGFR=80 at age 55-64 years). This complements comparisons within age group shown in panels A and B and comparisons of additive interaction shown on the bottom of panels C and D.
Following the published results from individual studies, we assumed the proportional hazards model provided the best summary of the data in each study and did not summarize statistics on deviations from proportionality across the covariates.
Additional notes for interaction analysis:
To assess overall interaction over the total range of eGFR, the coefficients of the product terms of the seven eGFR splines (<30, 30-44, 45-59, 60-74, 75-89, 90-104, ≥105 mL/min/1.73m 2 ) and dummy variables of age categories were averaged in each study using inverse-variance weighting. This average coefficient of the product terms indicates the average difference in log HR of outcome of interest for lower eGFR between age category of interest and reference age category (55-64 years). Subsequently the average coefficient of the product terms from each study was pooled using random-effect meta-analysis. This was repeated for log-ACR splines (<10, 10-29, 30-299, ≥300 mg/g). Results were presented as ratio of HRs (relative HRs) for mortality or ESRD according to 15 mL/min/1.73m 2 lower eGFR and 10-fold higher ACR in age category of interest (18-54, 65-74, or 75+ years) vs. reference age category (55-64 years).
We also tested the interaction by conducting meta-regression analysis with a random-effects model, which allowed us to assess the CKD-age interaction with studies only enrolling individuals aged 65 years and older (CHS, MRC Older People, and ULSAM).
For additive interaction, we tested whether the risk difference was equal across age groups. Differences in incidence rates were calculated for each point (eGFR and ACR value) and each age group compared to the reference value. For example, the mortality rate difference between eGFR=45 and the reference eGFR=80 was 85.0-57.2=27.2 deaths/1000 person years for the age group 75+ years. The risk difference was then compared to the corresponding rate difference in the reference age group of 55-64 years. For example, the mortality rate difference between eGFR=45 and the reference eGFR=80 was 22.3-10.1=12.2 deaths/1000 person years for this age group. The additive interaction is calculated as the difference between these two mortality rate differences and its sign (direction) is noted. In this example, the additive interaction is 27.2-12.2=15.0 death/1000 person years and it is noted as a positive interaction since its sign is positive, i.e. greater risk difference at age 75+ years compared to the reference age group. The standard errors for additive interaction (difference between incidence rate differences) was eAppendix 2. Data Analysis Overview and Analytic Notes for Some Individual Studies (continued) calculated using the delta method and the variance-covariance matrix of all the spline regression coefficients obtained using multi-variate meta-analysis and restricted maximum likelihood (REML) in STATA. It is useful to note that a single reference average incidence rate is combined with the adjusted hazard ratios to get all the adjusted average risks. Therefore, the reference average incidence rate itself does not affect statistical tests of risk differences or interactions. Using the same example, the average mortality risk of 10.1 deaths/1000 person years at eGFR=80 at age 55-64 years is a part of all average mortality rates. In this example above, the standard error for the additive interaction is 4.0 which is less than half the effect size and hence a p-value<0.05 and a "+" is plotted for point-wise additive interaction in panel C. Calculations were carried out for each point on the graphs (1 ml/min/1.73m2 of eGFR and 8% increment of ACR) maximizing the available information across studies. Since some studies did not include specific age categories or specific eGFR or ACR ranges within an age category they were excluded from those estimates. For interaction tests, studies had to have data in both age categories compared (age 75+ and the reference 55-64 in the example) for the specific eGFR or ACR value and the reference value examined (eGFR 45 vs. 80 in the example). Therefore, for interaction tests, meta analyses were repeated using this more restrictive requirement to utilize all available data without extrapolating studies to regions where they had no data. Thus, both sample sizes and effect sizes vary slightly from main effect graphs and interaction tests as well as across the full range of eGFR and ACR 
*Studies with ACR, †Studies with PCR ‡Proportion of participants with ACR ≥30 mg/g or PCR ≥50 mg/g or dipstick protein ≥1+. CKD prevalence is deflated for lack of persistence of micro-albuminuria on one visit to multiple visits using the methods in JAMA. 2007;298 (17):2038-2047. Those with microalbuminuria (ACR 30-299 mg/g) are assumed to have a persistence of 50.9% for those with eGFR >= 90 and 75.0% for those with eGFR of 60-89; conservatively the same criteria were applied to 1+ dipstick proteinuria (100% persistence is assumed for 2+ and ACR>=300 mg/g). ∩ Overall mean with range or SD for continuous variables.
All participants are included in AKDN (Dip) and thus are not accounted for in the total and median. * Hypothesis testing and 95% CI for attributable risks in Figure 3B is based on the adjusted hazard ratio Wald test and equivalence of the null hypothesis for hazard ratio (H0:HR=1) and risk difference (H0:AR=0 since AR=baseline risk *[HR-1]) for the comparison of each cell to the reference cell in the same age stratum. Thus, the 95% CI is the 95% CI for [HR-1] using the standard error of log(HR) from the univariate meta-analysis scaled up for the baseline risk in that stratum calculated as the baseline risk in the reference stratum times the adjusted hazard ratio of the given stratum compared to the reference startum for this reference cell. This calculation of confidence intervals focuses on the error for the comparisons within each stratum for the absolute risk excluding any error in the reference eGFRxACR cell. Estimates which incorporate the standard error in the reference cells gave similar patterns but had to rely on a different set of assumptions which were more restrictive in using multi-variate meta-analysis and normality of the attributable risks. 
